Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age
Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age
Active, not recruiting · NCT07207408 · Registry updated 2026-10-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age | Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis | Active, not recruiting | Phase 2 | 2026-10-05 | NCT07207408 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Dynavax Technologies Corporation | 2 |
| United States Department of Defense | 319 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| 103 | Miami | United States | 1 |
| AMR- El Dorado | El Dorado | United States | 1 |
| AMR- Las Vegas | Las Vegas | United States | 1 |
| CTI Clinical Research Center | Cincinnati | United States | 24 |